JNJ

Latest SEC Filings & News for JNJ

11 most recent filings and news items mentioning JNJ. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/JNJ/news?limit=20"

Pull JNJ filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day
Trading IdeasJun 22, 2026Neutral

AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition

AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition

View filing at SEC.gov →
NewsJun 17, 2026Neutral

'J&J Takes a Pass on Obesity Drugs to Focus Efforts on Cancer' - Bloomberg

'J&J Takes a Pass on Obesity Drugs to Focus Efforts on Cancer' - Bloomberg

View filing at SEC.gov →
NewsJun 15, 2026Neutral

Reported Saturday, Johnson & Johnson's TALVEY Plus DARZALEX FASPRO Delivers Up To 81% PFS And 89% OS At 24 Months In First Phase 3 Study To Show Superior PFS For GPRC5D Bispecific Combination In Multiple Myeloma

Reported Saturday, Johnson & Johnson's TALVEY Plus DARZALEX FASPRO Delivers Up To 81% PFS And 89% OS At 24 Months In First Phase 3 Study To Show Superior PFS For GPRC5D Bispecific Combination In Multiple Myeloma

View filing at SEC.gov →
NewsJun 15, 2026Neutral

Johnson & Johnson Plans $1B+ Florida Investment To Strengthen Its Vision Operations By Scaling Up Its Manufacturing, Packaging And Distribution Capabilities

Johnson & Johnson Plans $1B+ Florida Investment To Strengthen Its Vision Operations By Scaling Up Its Manufacturing, Packaging And Distribution Capabilities

View filing at SEC.gov →
NewsJun 11, 2026Neutral

Johnson & Johnson Says IMAAVY Showed Rapid And Durable Anemia Improvement In wAIHA, A Disease With No FDA-Approved Therapies

Johnson & Johnson Says IMAAVY Showed Rapid And Durable Anemia Improvement In wAIHA, A Disease With No FDA-Approved Therapies

View filing at SEC.gov →
NewsJun 11, 2026Neutral

Johnson & Johnson Expands US Roll-Out Of Latest Advancement In Presbyopia-Correcting Intraocular Lenses

Johnson & Johnson Expands US Roll-Out Of Latest Advancement In Presbyopia-Correcting Intraocular Lenses

View filing at SEC.gov →
BiotechJun 11, 2026Neutral

Johnson & Johnson Hits Target With IMAAVY In Rare Blood Disorder

Johnson & Johnson Hits Target With IMAAVY In Rare Blood Disorder

View filing at SEC.gov →
NewsJun 10, 2026Neutral

Johnson & Johnson Fined $32M From Los Angeles Jury Over 2024 Death Of California Woman From Pleural Mesothelioma Due To Exposure To Asbestos-Contaminated Talc Product

Johnson & Johnson Fined $32M From Los Angeles Jury Over 2024 Death Of California Woman From Pleural Mesothelioma Due To Exposure To Asbestos-Contaminated Talc Product

View filing at SEC.gov →
NewsJun 9, 2026Neutral

Johnson & Johnson's Nipocalimab Gets U.K.'s Medicines And Healthcare Products Regulatory Agency Authorization To Treat Adults And Adolescents With Generalised Myasthenia Gravis

Johnson & Johnson's Nipocalimab Gets U.K.'s Medicines And Healthcare Products Regulatory Agency Authorization To Treat Adults And Adolescents With Generalised Myasthenia Gravis

View filing at SEC.gov →
NewsJun 9, 2026Neutral

Johnson & Johnson Executive Speaking At Goldman Sachs Healthcare Conference Says Psoriasis Pill Icotyde Has Roughly 4,500 Prescribers Now, DTC Campaign Is Expected Soon

Johnson & Johnson Executive Speaking At Goldman Sachs Healthcare Conference Says Psoriasis Pill Icotyde Has Roughly 4,500 Prescribers Now, DTC Campaign Is Expected Soon

View filing at SEC.gov →
M&AJun 8, 2026Neutral

Johnson & Johnson To Acquire Firefly Bio For $1B In All-Cash Deal, Transaction To Complete Late 2026

Johnson & Johnson To Acquire Firefly Bio For $1B In All-Cash Deal, Transaction To Complete Late 2026

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.